CGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cognition Therapeutics Inc (CGTX) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has positive developments in its clinical trials, its financial performance is weak, and technical indicators do not suggest a clear upward trend. Given the lack of significant trading signals and the stock's current bearish trend, it is better to hold off on investing in CGTX at this time.
The MACD histogram is positive but contracting, indicating weakening momentum. RSI is neutral at 42.082, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.084, with key support at 1.021 and resistance at 1.147. Overall, the technical indicators suggest a bearish trend.
The company has received positive feedback from the FDA regarding its registrational path for zervimesine to treat dementia with Lewy bodies (DLB) psychosis. The SHIMMER study showed significant improvement in neuropsychiatric symptoms, addressing a critical unmet need in the market.
The company's financial performance is weak, with a significant YoY drop in net income (-50.39%) and EPS (-76.00%). Revenue remains at 0, showing no growth. Additionally, there is no significant trading activity from hedge funds, insiders, or Congress members.
In 2025/Q3, the company reported no revenue growth (0% YoY), a net income loss of -$4.93 million (-50.39% YoY), and a significant drop in EPS (-76.00% YoY). Gross margin remains at 0, indicating no profitability.
No recent analyst ratings or price target changes are available for CGTX.
